- Report
- March 2025
- 200 Pages
Global
From €4020EUR$4,490USD£3,499GBP
- Report
- March 2025
- 200 Pages
Global
From €4020EUR$4,490USD£3,499GBP
- Report
- August 2025
- 282 Pages
Global
From €5238EUR$5,850USD£4,559GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1343EUR$1,500USD£1,169GBP
- Report
- September 2024
- 343 Pages
Global
From €7119EUR$7,950USD£6,196GBP
- Report
- June 2025
- 150 Pages
Global
From €3358EUR$3,750USD£2,922GBP
- Report
- December 2024
- 30 Pages
Global
From €2462EUR$2,750USD£2,143GBP
- Report
- June 2025
- 400 Pages
Global
From €4431EUR$4,949USD£3,857GBP
- Report
- May 2021
- 50 Pages
China
From €2328EUR$2,600USD£2,026GBP
- Report
- May 2024
- 137 Pages
Global
From €5819EUR$6,499USD£5,065GBP
- Report
- July 2024
- 150 Pages
Global
From €3358EUR$3,750USD£2,922GBP
- Report
- November 2023
- 135 Pages
Global
From €3582EUR$4,000USD£3,117GBP
- Report
- April 2023
- 117 Pages
Global
From €4253EUR$4,750USD£3,702GBP
- Report
- March 2023
- 147 Pages
Global
From €4431EUR$4,949USD£3,857GBP
- Report
- January 2023
- 85 Pages
Europe
From €1343EUR$1,500USD£1,169GBP
- Report
- January 2024
- 114 Pages
United States
€3134EUR$3,500USD£2,728GBP
- Report
- January 2024
- 156 Pages
United States
€3403EUR$3,800USD£2,961GBP
- Report
- July 2018
- 33 Pages
Global
From €8954EUR$10,000USD£7,793GBP
- Report
- August 2025
- 50 Pages
Global
From €2373EUR$2,650USD£2,065GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more